NASDAQ:KPTI

Karyopharm Therapeutics Competitors

$10.02
-0.12 (-1.18 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.89
Now: $10.02
$10.22
50-Day Range
$9.85
MA: $12.12
$15.11
52-Week Range
$9.75
Now: $10.02
$25.98
Volume1.08 million shs
Average Volume2.58 million shs
Market Capitalization$747.83 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93

Competitors

Karyopharm Therapeutics (NASDAQ:KPTI) Vs. MOR, ORGO, VIE, OPK, TARO, and CORT

Should you be buying KPTI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Karyopharm Therapeutics, including MorphoSys (MOR), Organogenesis (ORGO), Viela Bio (VIE), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO), and Corcept Therapeutics (CORT).

MorphoSys (NASDAQ:MOR) and Karyopharm Therapeutics (NASDAQ:KPTI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares MorphoSys and Karyopharm Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million36.57$-115,380,000.00($0.91)-24.57
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11

MorphoSys has higher revenue and earnings than Karyopharm Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MorphoSys and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Analyst Recommendations

This is a summary of current recommendations and price targets for MorphoSys and Karyopharm Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys06402.40
Karyopharm Therapeutics01802.89

Karyopharm Therapeutics has a consensus price target of $30.6250, indicating a potential upside of 205.64%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

MorphoSys has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

MorphoSys beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Organogenesis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
Organogenesis$260.98 million11.20$-40,450,000.00($0.42)-54.38

Organogenesis has higher revenue and earnings than Karyopharm Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Organogenesis-1.61%-10.03%-2.22%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Organogenesis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Organogenesis00403.00

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 27.76%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Organogenesis.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 57.2% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

Summary

Organogenesis beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Viela Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Viela Bio has higher revenue and earnings than Karyopharm Therapeutics. Viela Bio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Viela BioN/A-33.97%-31.49%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Viela Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Viela Bio05202.29

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Viela Bio has a consensus target price of $57.00, indicating a potential upside of 7.53%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Viela Bio.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Karyopharm Therapeutics (NASDAQ:KPTI) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and OPKO Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
OPKO Health$901.90 million3.11$-314,920,000.00($0.41)-10.20

Karyopharm Therapeutics has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and OPKO Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
OPKO Health-9.79%-2.61%-1.80%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and OPKO Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
OPKO Health00203.00

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. OPKO Health has a consensus target price of $9.00, indicating a potential upside of 115.31%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than OPKO Health.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 40.9% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Summary

OPKO Health beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
Taro Pharmaceutical Industries$644.77 million4.32$244.24 million$6.3511.47

Taro Pharmaceutical Industries has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Taro Pharmaceutical Industries00103.00

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Taro Pharmaceutical Industries has a consensus target price of $81.00, indicating a potential upside of 11.22%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Taro Pharmaceutical Industries.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45

Corcept Therapeutics has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Corcept Therapeutics30.73%25.38%23.16%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Karyopharm Therapeutics and Corcept Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Corcept Therapeutics01102.50

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Corcept Therapeutics has a consensus target price of $24.00, indicating a potential upside of 5.82%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Corcept Therapeutics.

Risk & Volatility

Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Corcept Therapeutics beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.


Karyopharm Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.